MiNK Therapeutics (INKT)
NASDAQ:INKT
Want to see INKT full AI Analyst Report?
Total Valuation
MiNK Therapeutics has a market cap or net worth of $55.32M. The enterprise value is -$13.30B.
Market Cap$55.32M
Enterprise Value-$13.30B
Share Statistics
MiNK Therapeutics has 4,965,858 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,965,858
Owned by Insiders4.57%
Owned by Institutions<0.01%
Financial Efficiency
MiNK Therapeutics’s return on equity (ROE) is 0.88 and return on invested capital (ROIC) is -195.52%.
Return on Equity (ROE)0.88
Return on Assets (ROA)-0.88
Return on Invested Capital (ROIC)-195.52%
Return on Capital Employed (ROCE)-10.34
Revenue Per Employee0.00
Profits Per Employee-543.23M
Employee Count23
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of MiNK Therapeutics is ―. MiNK Therapeutics’s PEG ratio is -3.68.
PE Ratio―
PS Ratio0.00
PB Ratio-3.35
Price to Fair Value-3.35
Price to FCF>-0.01
Price to Operating Cash Flow-0.04
PEG Ratio-3.68
Income Statement
In the last 12 months, MiNK Therapeutics had revenue of 0.00 and earned -12.49M in profits. Earnings per share was -2.93.
Revenue0.00
Gross Profit-181.75K
Operating Income-12.49M
Pretax Income-12.49M
Net Income-12.49M
EBITDA-12.31M
Earnings Per Share (EPS)-2.93
Cash Flow
In the last 12 months, operating cash flow was -1.35B and capital expenditures -3.00, giving a free cash flow of -1.35B billion.
Operating Cash Flow-1.35B
Free Cash Flow-1.35B
Free Cash Flow per Share-270.94
Dividends & Yields
MiNK Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.10
52-Week Price Change46.04%
50-Day Moving Average10.94
200-Day Moving Average13.34
Relative Strength Index (RSI)68.46
Average Volume (3m)39.56K
Important Dates
MiNK Therapeutics upcoming earnings date is May 13, 2026, Before Open (Confirmed).
Last Earnings DateMar 31, 2026
Next Earnings DateMay 13, 2026
Ex-Dividend Date―
Financial Position
MiNK Therapeutics as a current ratio of 1.06, with Debt / Equity ratio of -36.40%
Current Ratio1.06
Quick Ratio1.06
Debt to Market Cap0.11
Net Debt to EBITDA1.09K
Interest Coverage Ratio0.00
Taxes
In the past 12 months, MiNK Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
MiNK Therapeutics EV to EBITDA ratio is 1.08K, with an EV/FCF ratio of 2.25.
EV to Sales0.00
EV to EBITDA1.08K
EV to Free Cash Flow2.25
EV to Operating Cash Flow2.25
Balance Sheet
MiNK Therapeutics has $13.36B in cash and marketable securities with $5.18M in debt, giving a net cash position of $13.36B billion.
Cash & Marketable Securities$13.36B
Total Debt$5.18M
Net Cash$13.36B
Net Cash Per Share$2.69K
Tangible Book Value Per Share-$3.33
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for MiNK Therapeutics is $35.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$35.00
Price Target Upside146.31% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast-1.96%